|
PSA (ng/ml)
|
Prostate cancer detection rate (%) (no./total no.)
|
|---|
|
Negative DRE
|
Positive DRE
|
Negative imaging
|
Positive imaging
|
|---|
|
0–4
|
29.7 (19/64)
|
33.3 (2/6)
|
27.5 (11/40)
|
66.7 (20/30)
|
|
4–10
|
13.5 (29/215)
|
58.2 (32/55)
|
11.2 (21/187)
|
48.2 (40/83)
|
|
10–20
|
25.6 (61/238)
|
59.6 (62/104)
|
25.7 (54/210)
|
52.3 (69/132)
|
|
20–100
|
55.6 (70/126)
|
62.8 (76/121)
|
54.4 (43/79)
|
61.3 (103/168)
|
|
≥ 100
|
0 (0/3)
|
96.7 (87/90)
|
0 (0/0)
|
100.0 (93/93)
|
|
Overall
|
27.7 (179/646)
|
68.9 (259/376)
|
25.0 (129/516)
|
64.2 (325/506)
|
-
DRE digital rectal examination, PSA prostatic-specific antigen
